Clinical relevance of urokinase plasminogen activator, its receptor, and its inhibitor in patients with renal cell carcinoma

Cancer

Volumn 78, Issue 3, 1996, Pages 487-492

  Hofmann, Rainer ^a,b   Lehmer, Antonie ^a   Buresch, Markus ^a   Hartung, Rudolf ^a   Ulm, Kurt ^a  

^a TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^b TECHNICAL UNIVERSITY OF MUNICH   (Germany)

Author keywords

plasminogen activator inhibitor PAI 1; prognostic factor; renal cell carcinoma; urokinase type plasminogen activator u PA

Indexed keywords

PLASMINOGEN ACTIVATOR INHIBITOR 1; RECEPTOR; UROKINASE; UROKINASE RECEPTOR;

ARTICLE; CANCER RECURRENCE; CANCER SURVIVAL; CONTROLLED STUDY; HUMAN; HUMAN TISSUE; KIDNEY CARCINOMA; MAJOR CLINICAL STUDY; METASTASIS; NEPHRECTOMY; PRIORITY JOURNAL; PROGNOSIS;

CARCINOMA, RENAL CELL; DISEASE-FREE SURVIVAL; ENZYME-LINKED IMMUNOSORBENT ASSAY; HUMANS; KIDNEY NEOPLASMS; LYMPHATIC METASTASIS; PLASMINOGEN ACTIVATOR INHIBITOR 1; PLASMINOGEN ACTIVATORS; PROGNOSIS; RECEPTORS, CELL SURFACE; TUMOR MARKERS, BIOLOGICAL; URINARY PLASMINOGEN ACTIVATOR;

EID: 0029898212     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0142(19960801)78:3<487::AID-CNCR16>3.0.CO;2-V     Document Type: Article

References (23)

1. Schmitt M, Jänicke F, Graeff H. Tumor-associated proteases. Fibrinolysis 6, 1992;(Suppl 4):3-26.
2. Mizukami I, Garni-Wagner BA, DeAngelo M, Liebert M, Flint A, Lawrence D, et al. Immunologic detection of the cellular receptor for urokinase plasminogen activator. Clin Immunol Immunopathol 1994;71(1):96-104.
3. Kariko K, Malkowicz SB, Li WJ, Kuo A, Barnathan ES. Invasive neoplastic uroepithelial cells express high levels of urokinase receptor and plasminogen receptor, a-enolase. Int J Oncol 1993;3:189-1095.
4. Schmitt M, Jänicke F, Graeff H. Tumor associated fibrinolysis: the prognostic relevance of plasminogen activators u-PA and t-PA in human breast cancer. Blood Coagul Fibrinolysis 1990;1:695-702.
5. Hollas W, Hoosein N, Chung LWK, Mazar A, Henkin J, Kariko K, et al. Expression of urokinase and its receptor in invasive and non-invasive prostate cancer cell lines. Thromb Haemost 1992;68:662-6.
6. Mitsubya S, Akiyama T, Kurita T, Okada K, Bando H, Sakai T, et al. Plasminogen activators in bladder tumors. Urol Res 1987;15:335-9.
7. Boyd G, Florent G, Kim P, Brittain M. Determination of the levels of urokinase and its receptor in human colon carcinoma cell lines. Cancer Res 1988;49:3112-6.
8. Jänicke F, Schmitt M, Graeff H. Clinical relevance of the urokinase type and tissue type plasminogen activators and of their type 1 inhibitor in breast cancer. Semin Thromb Hemost 1991;17:303-12.
9. Laiho M, Kski-Oja J. Growth factors in the regulation of pericellular proteolysis: a review. Cancer Res 1989;49:2533-53.
10. Cubellis MV, Wun TC, Blasi F. Receptor mediated internalisation and degradation of urokinase is caused by its specific inhibitor. EMBO J 1990;9:1079-85.
11. Vindelov L, Christensen IB, Nissen N. A detergent-trypsin method for the preparation of nuclei for flow cytometric DNA analysis. Cytometry 1983;3:323-7.
12. Hawkins DM. Testing the sequence of observations for a shift in location. JAMA 1977;72:180-6.
13. Keer HN, Gaylis FD, Kozlowski JM, Kwaan HC, Bauer KD, Sinha AA, et al. Heterogeneity in plasminogen activator (PA) levels in human prostate cancer cell lines: increased PA activity correlates with biologically aggressive behaviour. Prostate 1991;18:201-14.
14. See WA, Yong X, Crist S, Hedican S. Diversity and modulation of plasminogen activator activity in human transitional carcinoma cell lines. J Urol 1994;151:1691-6.
15. Yoshida E, Verrusio EN, Mihara H, Oh D, Kwaan HC. Enhancement of the expression of urokinase-type palsminogen activator from PC-3 human prostate cancer cells by thrombin. Cancer Res 1994;34:3300-4.
16. Stetler-Stevenson WG, Aznavoorian S, Liotta LA. Tumor cell interactions with the extracellular matrix during invasion and metastasis. Annu Rev Cell Biol 1993;9:541-73.
17. Wilhelm O, Weidle U, Höhl S, Rettenberger P, Schmitt M, Graeff H. Recombinant soluble urokinase receptor as a scavenger for urokinase type plasminogen activator (u-PA). FEBS Lett 1994;337:131-4.
18. Duffy JM, Reilly D, Nolan N, O'Higgins N, Fennelly JJ, Andreasen P. Urokinase plasminogen activator, a strong and independent prognostic marker in breast cancer. Fibrinolysis 6 1992;(Suppl 4):55-7.
19. Lehmann K, Plas E, Gautschi K, Hauri D. Prognostic value of urokinase plasmonogen activator for prostatic cancer. Urol Int 1994;52:159-61.
20. Heidtmann HH, Hofmann M, Jakob E, Erbil C, Havemann K. Synthesis and sectetion of plasminogen activators and plasminogen activator inhibitors in cell lines of different groups of human lung tumors. Cancer Res 1990;49:816-20.
21. Hansen SH, Behrendt N, Dano K, Kristiansen P. Localisation of urokinase type plasminogen activator receptor on U 937 cells: phorbol ester PMA induces heterogeneity. Exp Cell Res 1990;187:255-62.
22. Estreicher A, Muhlhauser J, Carpentier JL, Orci I, Vasalli JD. The receptor of urokinase type plasinogen activator polarizes expression of the protease to the leading edge of migrating monocytes and promotes degradation of enzyme inhibitor complexes. J Cell Biol 1990;111:783-92.
23. Cubellis MV, Andreasen P, Ragno P, Mayer M, Dano K, Blasi F. Accessibility of receptor bound urokinase to type 1 plasminogen activator inhibitor. Proc Natl Acad Sci USA 1989;86:4828-32.